nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—MAP2K1—prostate cancer	0.389	0.895	CbGaD
Trametinib—CYP3A4—prostate cancer	0.0454	0.104	CbGaD
Trametinib—CYP2C8—Nilutamide—prostate cancer	0.0393	0.137	CbGbCtD
Trametinib—CYP2C8—Abiraterone—prostate cancer	0.0325	0.114	CbGbCtD
Trametinib—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0303	0.106	CbGbCtD
Trametinib—CYP2C8—Cabazitaxel—prostate cancer	0.0241	0.0842	CbGbCtD
Trametinib—CYP2C8—Ethinyl Estradiol—prostate cancer	0.021	0.0734	CbGbCtD
Trametinib—CYP3A4—Bicalutamide—prostate cancer	0.0159	0.0557	CbGbCtD
Trametinib—CYP3A4—Estramustine—prostate cancer	0.0148	0.0518	CbGbCtD
Trametinib—CYP2C8—Estradiol—prostate cancer	0.0135	0.0473	CbGbCtD
Trametinib—CYP3A4—Flutamide—prostate cancer	0.0132	0.0462	CbGbCtD
Trametinib—CYP3A4—Abiraterone—prostate cancer	0.0132	0.0462	CbGbCtD
Trametinib—CYP3A4—Cabazitaxel—prostate cancer	0.00976	0.0341	CbGbCtD
Trametinib—CYP3A4—Estrone—prostate cancer	0.00954	0.0334	CbGbCtD
Trametinib—CYP2C8—Etoposide—prostate cancer	0.00882	0.0309	CbGbCtD
Trametinib—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0085	0.0297	CbGbCtD
Trametinib—CYP3A4—Conjugated Estrogens—prostate cancer	0.00624	0.0218	CbGbCtD
Trametinib—CYP3A4—Mitoxantrone—prostate cancer	0.00567	0.0198	CbGbCtD
Trametinib—CYP3A4—Estradiol—prostate cancer	0.00548	0.0192	CbGbCtD
Trametinib—CYP3A4—Prednisone—prostate cancer	0.00471	0.0165	CbGbCtD
Trametinib—CYP3A4—Etoposide—prostate cancer	0.00358	0.0125	CbGbCtD
Trametinib—CYP3A4—Docetaxel—prostate cancer	0.00327	0.0115	CbGbCtD
Trametinib—MAP2K1—prostate gland—prostate cancer	0.00299	0.115	CbGeAlD
Trametinib—MAP2K2—prostate gland—prostate cancer	0.00263	0.101	CbGeAlD
Trametinib—CYP3A4—Doxorubicin—prostate cancer	0.00244	0.00854	CbGbCtD
Trametinib—MAP2K2—seminal vesicle—prostate cancer	0.00223	0.0857	CbGeAlD
Trametinib—MAP2K1—epithelium—prostate cancer	0.0022	0.0846	CbGeAlD
Trametinib—MAP2K1—renal system—prostate cancer	0.00204	0.0785	CbGeAlD
Trametinib—MAP2K2—renal system—prostate cancer	0.00179	0.0691	CbGeAlD
Trametinib—MAP2K2—urethra—prostate cancer	0.00176	0.0679	CbGeAlD
Trametinib—CYP3A4—urine—prostate cancer	0.00172	0.0662	CbGeAlD
Trametinib—MAP2K1—bone marrow—prostate cancer	0.00154	0.0593	CbGeAlD
Trametinib—MAP2K2—bone marrow—prostate cancer	0.00136	0.0522	CbGeAlD
Trametinib—MAP2K1—testis—prostate cancer	0.00132	0.0507	CbGeAlD
Trametinib—MAP2K2—testis—prostate cancer	0.00116	0.0447	CbGeAlD
Trametinib—MAP2K1—lymph node—prostate cancer	0.000955	0.0368	CbGeAlD
Trametinib—MAP2K2—lymph node—prostate cancer	0.000841	0.0324	CbGeAlD
Trametinib—CYP2C8—renal system—prostate cancer	0.000621	0.0239	CbGeAlD
Trametinib—CYP3A4—renal system—prostate cancer	0.000421	0.0162	CbGeAlD
Trametinib—CYP2C8—testis—prostate cancer	0.000402	0.0155	CbGeAlD
Trametinib—Asthenia—Estradiol—prostate cancer	4.07e-05	0.00031	CcSEcCtD
Trametinib—Neutropenia—Epirubicin—prostate cancer	4.05e-05	0.000309	CcSEcCtD
Trametinib—Angiopathy—Prednisone—prostate cancer	4.02e-05	0.000307	CcSEcCtD
Trametinib—Pruritus—Estradiol—prostate cancer	4.01e-05	0.000306	CcSEcCtD
Trametinib—Leukopenia—Docetaxel—prostate cancer	4.01e-05	0.000305	CcSEcCtD
Trametinib—Anaemia—Capecitabine—prostate cancer	4.01e-05	0.000305	CcSEcCtD
Trametinib—Arrhythmia—Prednisone—prostate cancer	3.96e-05	0.000302	CcSEcCtD
Trametinib—Pancreatitis—Doxorubicin—prostate cancer	3.93e-05	0.0003	CcSEcCtD
Trametinib—Hyperglycaemia—Epirubicin—prostate cancer	3.91e-05	0.000298	CcSEcCtD
Trametinib—Cough—Docetaxel—prostate cancer	3.91e-05	0.000298	CcSEcCtD
Trametinib—Mental disorder—Prednisone—prostate cancer	3.89e-05	0.000296	CcSEcCtD
Trametinib—Diarrhoea—Estradiol—prostate cancer	3.88e-05	0.000296	CcSEcCtD
Trametinib—Leukopenia—Capecitabine—prostate cancer	3.88e-05	0.000296	CcSEcCtD
Trametinib—Hypertension—Docetaxel—prostate cancer	3.86e-05	0.000295	CcSEcCtD
Trametinib—Infestation NOS—Epirubicin—prostate cancer	3.86e-05	0.000294	CcSEcCtD
Trametinib—Infestation—Epirubicin—prostate cancer	3.86e-05	0.000294	CcSEcCtD
Trametinib—Erythema—Prednisone—prostate cancer	3.86e-05	0.000294	CcSEcCtD
Trametinib—Malnutrition—Prednisone—prostate cancer	3.86e-05	0.000294	CcSEcCtD
Trametinib—Decreased appetite—Etoposide—prostate cancer	3.82e-05	0.000291	CcSEcCtD
Trametinib—Myalgia—Docetaxel—prostate cancer	3.81e-05	0.00029	CcSEcCtD
Trametinib—Arthralgia—Docetaxel—prostate cancer	3.81e-05	0.00029	CcSEcCtD
Trametinib—Renal failure—Epirubicin—prostate cancer	3.8e-05	0.000289	CcSEcCtD
Trametinib—Gastrointestinal disorder—Etoposide—prostate cancer	3.8e-05	0.000289	CcSEcCtD
Trametinib—Asthenia—Mitoxantrone—prostate cancer	3.79e-05	0.000289	CcSEcCtD
Trametinib—Fatigue—Etoposide—prostate cancer	3.79e-05	0.000289	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	3.78e-05	0.000288	CcSEcCtD
Trametinib—Cough—Capecitabine—prostate cancer	3.78e-05	0.000288	CcSEcCtD
Trametinib—Stomatitis—Epirubicin—prostate cancer	3.77e-05	0.000287	CcSEcCtD
Trametinib—Constipation—Etoposide—prostate cancer	3.76e-05	0.000286	CcSEcCtD
Trametinib—Urinary tract infection—Epirubicin—prostate cancer	3.76e-05	0.000286	CcSEcCtD
Trametinib—Dizziness—Estradiol—prostate cancer	3.75e-05	0.000286	CcSEcCtD
Trametinib—Neutropenia—Doxorubicin—prostate cancer	3.75e-05	0.000286	CcSEcCtD
Trametinib—Hypertension—Capecitabine—prostate cancer	3.74e-05	0.000285	CcSEcCtD
Trametinib—Dry mouth—Docetaxel—prostate cancer	3.73e-05	0.000284	CcSEcCtD
Trametinib—Arthralgia—Capecitabine—prostate cancer	3.69e-05	0.000281	CcSEcCtD
Trametinib—Myalgia—Capecitabine—prostate cancer	3.69e-05	0.000281	CcSEcCtD
Trametinib—Haematuria—Epirubicin—prostate cancer	3.68e-05	0.000281	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	3.66e-05	0.000279	CcSEcCtD
Trametinib—Oedema—Docetaxel—prostate cancer	3.65e-05	0.000278	CcSEcCtD
Trametinib—Epistaxis—Epirubicin—prostate cancer	3.64e-05	0.000278	CcSEcCtD
Trametinib—Vision blurred—Prednisone—prostate cancer	3.64e-05	0.000277	CcSEcCtD
Trametinib—Infection—Docetaxel—prostate cancer	3.63e-05	0.000277	CcSEcCtD
Trametinib—Hyperglycaemia—Doxorubicin—prostate cancer	3.62e-05	0.000276	CcSEcCtD
Trametinib—Diarrhoea—Mitoxantrone—prostate cancer	3.62e-05	0.000276	CcSEcCtD
Trametinib—Dry mouth—Capecitabine—prostate cancer	3.61e-05	0.000275	CcSEcCtD
Trametinib—Vomiting—Estradiol—prostate cancer	3.61e-05	0.000275	CcSEcCtD
Trametinib—Gastrointestinal pain—Etoposide—prostate cancer	3.59e-05	0.000274	CcSEcCtD
Trametinib—Nervous system disorder—Docetaxel—prostate cancer	3.58e-05	0.000273	CcSEcCtD
Trametinib—Thrombocytopenia—Docetaxel—prostate cancer	3.58e-05	0.000273	CcSEcCtD
Trametinib—Rash—Estradiol—prostate cancer	3.58e-05	0.000273	CcSEcCtD
Trametinib—Infestation—Doxorubicin—prostate cancer	3.57e-05	0.000272	CcSEcCtD
Trametinib—Infestation NOS—Doxorubicin—prostate cancer	3.57e-05	0.000272	CcSEcCtD
Trametinib—Dermatitis—Estradiol—prostate cancer	3.57e-05	0.000272	CcSEcCtD
Trametinib—Anaemia—Prednisone—prostate cancer	3.57e-05	0.000272	CcSEcCtD
Trametinib—Headache—Estradiol—prostate cancer	3.55e-05	0.000271	CcSEcCtD
Trametinib—Skin disorder—Docetaxel—prostate cancer	3.55e-05	0.00027	CcSEcCtD
Trametinib—Oedema—Capecitabine—prostate cancer	3.54e-05	0.00027	CcSEcCtD
Trametinib—Bradycardia—Epirubicin—prostate cancer	3.53e-05	0.000269	CcSEcCtD
Trametinib—Renal failure—Doxorubicin—prostate cancer	3.51e-05	0.000268	CcSEcCtD
Trametinib—Infection—Capecitabine—prostate cancer	3.51e-05	0.000268	CcSEcCtD
Trametinib—Haemoglobin—Epirubicin—prostate cancer	3.49e-05	0.000266	CcSEcCtD
Trametinib—Stomatitis—Doxorubicin—prostate cancer	3.48e-05	0.000266	CcSEcCtD
Trametinib—Abdominal pain—Etoposide—prostate cancer	3.48e-05	0.000265	CcSEcCtD
Trametinib—Body temperature increased—Etoposide—prostate cancer	3.48e-05	0.000265	CcSEcCtD
Trametinib—Urinary tract infection—Doxorubicin—prostate cancer	3.47e-05	0.000265	CcSEcCtD
Trametinib—Nervous system disorder—Capecitabine—prostate cancer	3.47e-05	0.000264	CcSEcCtD
Trametinib—Haemorrhage—Epirubicin—prostate cancer	3.47e-05	0.000264	CcSEcCtD
Trametinib—Thrombocytopenia—Capecitabine—prostate cancer	3.46e-05	0.000264	CcSEcCtD
Trametinib—Skin disorder—Capecitabine—prostate cancer	3.44e-05	0.000262	CcSEcCtD
Trametinib—Urinary tract disorder—Epirubicin—prostate cancer	3.43e-05	0.000261	CcSEcCtD
Trametinib—Hyperhidrosis—Capecitabine—prostate cancer	3.42e-05	0.000261	CcSEcCtD
Trametinib—Oedema peripheral—Epirubicin—prostate cancer	3.42e-05	0.00026	CcSEcCtD
Trametinib—Haematuria—Doxorubicin—prostate cancer	3.41e-05	0.00026	CcSEcCtD
Trametinib—Connective tissue disorder—Epirubicin—prostate cancer	3.41e-05	0.00026	CcSEcCtD
Trametinib—Urethral disorder—Epirubicin—prostate cancer	3.4e-05	0.000259	CcSEcCtD
Trametinib—Epistaxis—Doxorubicin—prostate cancer	3.37e-05	0.000257	CcSEcCtD
Trametinib—Nausea—Estradiol—prostate cancer	3.37e-05	0.000257	CcSEcCtD
Trametinib—Vomiting—Mitoxantrone—prostate cancer	3.36e-05	0.000256	CcSEcCtD
Trametinib—Hypertension—Prednisone—prostate cancer	3.33e-05	0.000254	CcSEcCtD
Trametinib—Rash—Mitoxantrone—prostate cancer	3.33e-05	0.000254	CcSEcCtD
Trametinib—Dermatitis—Mitoxantrone—prostate cancer	3.33e-05	0.000254	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Docetaxel—prostate cancer	3.33e-05	0.000254	CcSEcCtD
Trametinib—Headache—Mitoxantrone—prostate cancer	3.31e-05	0.000252	CcSEcCtD
Trametinib—Insomnia—Docetaxel—prostate cancer	3.3e-05	0.000252	CcSEcCtD
Trametinib—Myalgia—Prednisone—prostate cancer	3.29e-05	0.00025	CcSEcCtD
Trametinib—Arthralgia—Prednisone—prostate cancer	3.29e-05	0.00025	CcSEcCtD
Trametinib—Bradycardia—Doxorubicin—prostate cancer	3.27e-05	0.000249	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	3.26e-05	0.000249	CcSEcCtD
Trametinib—Eye disorder—Epirubicin—prostate cancer	3.24e-05	0.000247	CcSEcCtD
Trametinib—Haemoglobin—Doxorubicin—prostate cancer	3.23e-05	0.000246	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Capecitabine—prostate cancer	3.22e-05	0.000246	CcSEcCtD
Trametinib—Cardiac disorder—Epirubicin—prostate cancer	3.22e-05	0.000245	CcSEcCtD
Trametinib—Haemorrhage—Doxorubicin—prostate cancer	3.21e-05	0.000245	CcSEcCtD
Trametinib—Insomnia—Capecitabine—prostate cancer	3.2e-05	0.000244	CcSEcCtD
Trametinib—Decreased appetite—Docetaxel—prostate cancer	3.18e-05	0.000242	CcSEcCtD
Trametinib—Urinary tract disorder—Doxorubicin—prostate cancer	3.17e-05	0.000242	CcSEcCtD
Trametinib—Oedema peripheral—Doxorubicin—prostate cancer	3.16e-05	0.000241	CcSEcCtD
Trametinib—Gastrointestinal disorder—Docetaxel—prostate cancer	3.15e-05	0.00024	CcSEcCtD
Trametinib—Asthenia—Etoposide—prostate cancer	3.15e-05	0.00024	CcSEcCtD
Trametinib—Connective tissue disorder—Doxorubicin—prostate cancer	3.15e-05	0.00024	CcSEcCtD
Trametinib—Oedema—Prednisone—prostate cancer	3.15e-05	0.00024	CcSEcCtD
Trametinib—Fatigue—Docetaxel—prostate cancer	3.15e-05	0.00024	CcSEcCtD
Trametinib—Angiopathy—Epirubicin—prostate cancer	3.15e-05	0.00024	CcSEcCtD
Trametinib—Urethral disorder—Doxorubicin—prostate cancer	3.15e-05	0.00024	CcSEcCtD
Trametinib—Nausea—Mitoxantrone—prostate cancer	3.14e-05	0.000239	CcSEcCtD
Trametinib—Infection—Prednisone—prostate cancer	3.13e-05	0.000239	CcSEcCtD
Trametinib—Mediastinal disorder—Epirubicin—prostate cancer	3.13e-05	0.000238	CcSEcCtD
Trametinib—Constipation—Docetaxel—prostate cancer	3.12e-05	0.000238	CcSEcCtD
Trametinib—Chills—Epirubicin—prostate cancer	3.11e-05	0.000237	CcSEcCtD
Trametinib—Pruritus—Etoposide—prostate cancer	3.11e-05	0.000237	CcSEcCtD
Trametinib—Arrhythmia—Epirubicin—prostate cancer	3.1e-05	0.000236	CcSEcCtD
Trametinib—Nervous system disorder—Prednisone—prostate cancer	3.09e-05	0.000235	CcSEcCtD
Trametinib—Decreased appetite—Capecitabine—prostate cancer	3.07e-05	0.000234	CcSEcCtD
Trametinib—Skin disorder—Prednisone—prostate cancer	3.06e-05	0.000233	CcSEcCtD
Trametinib—Gastrointestinal disorder—Capecitabine—prostate cancer	3.05e-05	0.000233	CcSEcCtD
Trametinib—Fatigue—Capecitabine—prostate cancer	3.05e-05	0.000232	CcSEcCtD
Trametinib—Hyperhidrosis—Prednisone—prostate cancer	3.05e-05	0.000232	CcSEcCtD
Trametinib—Mental disorder—Epirubicin—prostate cancer	3.04e-05	0.000232	CcSEcCtD
Trametinib—Constipation—Capecitabine—prostate cancer	3.02e-05	0.00023	CcSEcCtD
Trametinib—Erythema—Epirubicin—prostate cancer	3.02e-05	0.00023	CcSEcCtD
Trametinib—Malnutrition—Epirubicin—prostate cancer	3.02e-05	0.00023	CcSEcCtD
Trametinib—Diarrhoea—Etoposide—prostate cancer	3.01e-05	0.000229	CcSEcCtD
Trametinib—Eye disorder—Doxorubicin—prostate cancer	3e-05	0.000229	CcSEcCtD
Trametinib—Gastrointestinal pain—Docetaxel—prostate cancer	2.99e-05	0.000228	CcSEcCtD
Trametinib—Cardiac disorder—Doxorubicin—prostate cancer	2.98e-05	0.000227	CcSEcCtD
Trametinib—Dysgeusia—Epirubicin—prostate cancer	2.96e-05	0.000225	CcSEcCtD
Trametinib—Back pain—Epirubicin—prostate cancer	2.92e-05	0.000223	CcSEcCtD
Trametinib—Angiopathy—Doxorubicin—prostate cancer	2.91e-05	0.000222	CcSEcCtD
Trametinib—Dizziness—Etoposide—prostate cancer	2.91e-05	0.000222	CcSEcCtD
Trametinib—Muscle spasms—Epirubicin—prostate cancer	2.9e-05	0.000221	CcSEcCtD
Trametinib—Gastrointestinal pain—Capecitabine—prostate cancer	2.89e-05	0.00022	CcSEcCtD
Trametinib—Mediastinal disorder—Doxorubicin—prostate cancer	2.89e-05	0.00022	CcSEcCtD
Trametinib—Abdominal pain—Docetaxel—prostate cancer	2.89e-05	0.00022	CcSEcCtD
Trametinib—Body temperature increased—Docetaxel—prostate cancer	2.89e-05	0.00022	CcSEcCtD
Trametinib—Chills—Doxorubicin—prostate cancer	2.88e-05	0.000219	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Prednisone—prostate cancer	2.87e-05	0.000219	CcSEcCtD
Trametinib—Arrhythmia—Doxorubicin—prostate cancer	2.87e-05	0.000218	CcSEcCtD
Trametinib—Insomnia—Prednisone—prostate cancer	2.85e-05	0.000217	CcSEcCtD
Trametinib—Vision blurred—Epirubicin—prostate cancer	2.85e-05	0.000217	CcSEcCtD
Trametinib—Mental disorder—Doxorubicin—prostate cancer	2.81e-05	0.000214	CcSEcCtD
Trametinib—Body temperature increased—Capecitabine—prostate cancer	2.8e-05	0.000213	CcSEcCtD
Trametinib—Abdominal pain—Capecitabine—prostate cancer	2.8e-05	0.000213	CcSEcCtD
Trametinib—Vomiting—Etoposide—prostate cancer	2.8e-05	0.000213	CcSEcCtD
Trametinib—Erythema—Doxorubicin—prostate cancer	2.79e-05	0.000213	CcSEcCtD
Trametinib—Malnutrition—Doxorubicin—prostate cancer	2.79e-05	0.000213	CcSEcCtD
Trametinib—Anaemia—Epirubicin—prostate cancer	2.79e-05	0.000213	CcSEcCtD
Trametinib—Rash—Etoposide—prostate cancer	2.77e-05	0.000211	CcSEcCtD
Trametinib—Dermatitis—Etoposide—prostate cancer	2.77e-05	0.000211	CcSEcCtD
Trametinib—Headache—Etoposide—prostate cancer	2.75e-05	0.00021	CcSEcCtD
Trametinib—Decreased appetite—Prednisone—prostate cancer	2.74e-05	0.000209	CcSEcCtD
Trametinib—Dysgeusia—Doxorubicin—prostate cancer	2.74e-05	0.000208	CcSEcCtD
Trametinib—Fatigue—Prednisone—prostate cancer	2.72e-05	0.000207	CcSEcCtD
Trametinib—Leukopenia—Epirubicin—prostate cancer	2.7e-05	0.000206	CcSEcCtD
Trametinib—Back pain—Doxorubicin—prostate cancer	2.7e-05	0.000206	CcSEcCtD
Trametinib—Constipation—Prednisone—prostate cancer	2.69e-05	0.000205	CcSEcCtD
Trametinib—Muscle spasms—Doxorubicin—prostate cancer	2.69e-05	0.000205	CcSEcCtD
Trametinib—Cough—Epirubicin—prostate cancer	2.63e-05	0.000201	CcSEcCtD
Trametinib—Vision blurred—Doxorubicin—prostate cancer	2.63e-05	0.000201	CcSEcCtD
Trametinib—Asthenia—Docetaxel—prostate cancer	2.62e-05	0.0002	CcSEcCtD
Trametinib—Nausea—Etoposide—prostate cancer	2.61e-05	0.000199	CcSEcCtD
Trametinib—Hypertension—Epirubicin—prostate cancer	2.61e-05	0.000199	CcSEcCtD
Trametinib—Pruritus—Docetaxel—prostate cancer	2.58e-05	0.000197	CcSEcCtD
Trametinib—Anaemia—Doxorubicin—prostate cancer	2.58e-05	0.000197	CcSEcCtD
Trametinib—Gastrointestinal pain—Prednisone—prostate cancer	2.58e-05	0.000196	CcSEcCtD
Trametinib—Arthralgia—Epirubicin—prostate cancer	2.57e-05	0.000196	CcSEcCtD
Trametinib—Myalgia—Epirubicin—prostate cancer	2.57e-05	0.000196	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	2.55e-05	0.000195	CcSEcCtD
Trametinib—Asthenia—Capecitabine—prostate cancer	2.54e-05	0.000193	CcSEcCtD
Trametinib—Dry mouth—Epirubicin—prostate cancer	2.51e-05	0.000192	CcSEcCtD
Trametinib—Pruritus—Capecitabine—prostate cancer	2.5e-05	0.000191	CcSEcCtD
Trametinib—Leukopenia—Doxorubicin—prostate cancer	2.5e-05	0.000191	CcSEcCtD
Trametinib—Diarrhoea—Docetaxel—prostate cancer	2.5e-05	0.00019	CcSEcCtD
Trametinib—Body temperature increased—Prednisone—prostate cancer	2.49e-05	0.00019	CcSEcCtD
Trametinib—Abdominal pain—Prednisone—prostate cancer	2.49e-05	0.00019	CcSEcCtD
Trametinib—Oedema—Epirubicin—prostate cancer	2.46e-05	0.000188	CcSEcCtD
Trametinib—Infection—Epirubicin—prostate cancer	2.45e-05	0.000187	CcSEcCtD
Trametinib—Cough—Doxorubicin—prostate cancer	2.44e-05	0.000186	CcSEcCtD
Trametinib—Diarrhoea—Capecitabine—prostate cancer	2.42e-05	0.000184	CcSEcCtD
Trametinib—Nervous system disorder—Epirubicin—prostate cancer	2.42e-05	0.000184	CcSEcCtD
Trametinib—Dizziness—Docetaxel—prostate cancer	2.42e-05	0.000184	CcSEcCtD
Trametinib—Thrombocytopenia—Epirubicin—prostate cancer	2.41e-05	0.000184	CcSEcCtD
Trametinib—Hypertension—Doxorubicin—prostate cancer	2.41e-05	0.000184	CcSEcCtD
Trametinib—Skin disorder—Epirubicin—prostate cancer	2.39e-05	0.000182	CcSEcCtD
Trametinib—Hyperhidrosis—Epirubicin—prostate cancer	2.38e-05	0.000182	CcSEcCtD
Trametinib—Arthralgia—Doxorubicin—prostate cancer	2.38e-05	0.000181	CcSEcCtD
Trametinib—Myalgia—Doxorubicin—prostate cancer	2.38e-05	0.000181	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.36e-05	0.00018	CcSEcCtD
Trametinib—Dizziness—Capecitabine—prostate cancer	2.34e-05	0.000178	CcSEcCtD
Trametinib—Dry mouth—Doxorubicin—prostate cancer	2.33e-05	0.000177	CcSEcCtD
Trametinib—Vomiting—Docetaxel—prostate cancer	2.32e-05	0.000177	CcSEcCtD
Trametinib—Rash—Docetaxel—prostate cancer	2.3e-05	0.000176	CcSEcCtD
Trametinib—Dermatitis—Docetaxel—prostate cancer	2.3e-05	0.000175	CcSEcCtD
Trametinib—Headache—Docetaxel—prostate cancer	2.29e-05	0.000174	CcSEcCtD
Trametinib—Oedema—Doxorubicin—prostate cancer	2.28e-05	0.000174	CcSEcCtD
Trametinib—Infection—Doxorubicin—prostate cancer	2.27e-05	0.000173	CcSEcCtD
Trametinib—Asthenia—Prednisone—prostate cancer	2.26e-05	0.000172	CcSEcCtD
Trametinib—Vomiting—Capecitabine—prostate cancer	2.25e-05	0.000171	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.25e-05	0.000171	CcSEcCtD
Trametinib—Nervous system disorder—Doxorubicin—prostate cancer	2.24e-05	0.00017	CcSEcCtD
Trametinib—Thrombocytopenia—Doxorubicin—prostate cancer	2.23e-05	0.00017	CcSEcCtD
Trametinib—Rash—Capecitabine—prostate cancer	2.23e-05	0.00017	CcSEcCtD
Trametinib—Pruritus—Prednisone—prostate cancer	2.23e-05	0.00017	CcSEcCtD
Trametinib—Insomnia—Epirubicin—prostate cancer	2.23e-05	0.00017	CcSEcCtD
Trametinib—Dermatitis—Capecitabine—prostate cancer	2.23e-05	0.00017	CcSEcCtD
Trametinib—Headache—Capecitabine—prostate cancer	2.22e-05	0.000169	CcSEcCtD
Trametinib—Skin disorder—Doxorubicin—prostate cancer	2.21e-05	0.000169	CcSEcCtD
Trametinib—Hyperhidrosis—Doxorubicin—prostate cancer	2.2e-05	0.000168	CcSEcCtD
Trametinib—Nausea—Docetaxel—prostate cancer	2.17e-05	0.000165	CcSEcCtD
Trametinib—Diarrhoea—Prednisone—prostate cancer	2.16e-05	0.000164	CcSEcCtD
Trametinib—Decreased appetite—Epirubicin—prostate cancer	2.14e-05	0.000163	CcSEcCtD
Trametinib—Gastrointestinal disorder—Epirubicin—prostate cancer	2.13e-05	0.000162	CcSEcCtD
Trametinib—Fatigue—Epirubicin—prostate cancer	2.12e-05	0.000162	CcSEcCtD
Trametinib—Constipation—Epirubicin—prostate cancer	2.11e-05	0.000161	CcSEcCtD
Trametinib—Nausea—Capecitabine—prostate cancer	2.1e-05	0.00016	CcSEcCtD
Trametinib—Dizziness—Prednisone—prostate cancer	2.08e-05	0.000159	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.08e-05	0.000158	CcSEcCtD
Trametinib—Insomnia—Doxorubicin—prostate cancer	2.06e-05	0.000157	CcSEcCtD
Trametinib—Gastrointestinal pain—Epirubicin—prostate cancer	2.02e-05	0.000154	CcSEcCtD
Trametinib—Vomiting—Prednisone—prostate cancer	2e-05	0.000153	CcSEcCtD
Trametinib—Rash—Prednisone—prostate cancer	1.99e-05	0.000151	CcSEcCtD
Trametinib—Dermatitis—Prednisone—prostate cancer	1.98e-05	0.000151	CcSEcCtD
Trametinib—Decreased appetite—Doxorubicin—prostate cancer	1.98e-05	0.000151	CcSEcCtD
Trametinib—Headache—Prednisone—prostate cancer	1.97e-05	0.00015	CcSEcCtD
Trametinib—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.97e-05	0.00015	CcSEcCtD
Trametinib—Fatigue—Doxorubicin—prostate cancer	1.97e-05	0.00015	CcSEcCtD
Trametinib—Constipation—Doxorubicin—prostate cancer	1.95e-05	0.000149	CcSEcCtD
Trametinib—Body temperature increased—Epirubicin—prostate cancer	1.95e-05	0.000148	CcSEcCtD
Trametinib—Abdominal pain—Epirubicin—prostate cancer	1.95e-05	0.000148	CcSEcCtD
Trametinib—Nausea—Prednisone—prostate cancer	1.87e-05	0.000143	CcSEcCtD
Trametinib—Gastrointestinal pain—Doxorubicin—prostate cancer	1.86e-05	0.000142	CcSEcCtD
Trametinib—Abdominal pain—Doxorubicin—prostate cancer	1.8e-05	0.000137	CcSEcCtD
Trametinib—Body temperature increased—Doxorubicin—prostate cancer	1.8e-05	0.000137	CcSEcCtD
Trametinib—Asthenia—Epirubicin—prostate cancer	1.77e-05	0.000135	CcSEcCtD
Trametinib—Pruritus—Epirubicin—prostate cancer	1.74e-05	0.000133	CcSEcCtD
Trametinib—Diarrhoea—Epirubicin—prostate cancer	1.69e-05	0.000128	CcSEcCtD
Trametinib—Asthenia—Doxorubicin—prostate cancer	1.64e-05	0.000125	CcSEcCtD
Trametinib—Dizziness—Epirubicin—prostate cancer	1.63e-05	0.000124	CcSEcCtD
Trametinib—Pruritus—Doxorubicin—prostate cancer	1.61e-05	0.000123	CcSEcCtD
Trametinib—Vomiting—Epirubicin—prostate cancer	1.57e-05	0.000119	CcSEcCtD
Trametinib—Diarrhoea—Doxorubicin—prostate cancer	1.56e-05	0.000119	CcSEcCtD
Trametinib—Rash—Epirubicin—prostate cancer	1.55e-05	0.000118	CcSEcCtD
Trametinib—Dermatitis—Epirubicin—prostate cancer	1.55e-05	0.000118	CcSEcCtD
Trametinib—Headache—Epirubicin—prostate cancer	1.54e-05	0.000118	CcSEcCtD
Trametinib—Dizziness—Doxorubicin—prostate cancer	1.51e-05	0.000115	CcSEcCtD
Trametinib—Nausea—Epirubicin—prostate cancer	1.46e-05	0.000112	CcSEcCtD
Trametinib—Vomiting—Doxorubicin—prostate cancer	1.45e-05	0.00011	CcSEcCtD
Trametinib—Rash—Doxorubicin—prostate cancer	1.44e-05	0.00011	CcSEcCtD
Trametinib—Dermatitis—Doxorubicin—prostate cancer	1.44e-05	0.000109	CcSEcCtD
Trametinib—Headache—Doxorubicin—prostate cancer	1.43e-05	0.000109	CcSEcCtD
Trametinib—Nausea—Doxorubicin—prostate cancer	1.35e-05	0.000103	CcSEcCtD
Trametinib—MAP2K1—Disease—ERBB2—prostate cancer	2.62e-06	2.14e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—LEP—prostate cancer	2.62e-06	2.14e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—BAD—prostate cancer	2.61e-06	2.13e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—IL6—prostate cancer	2.6e-06	2.12e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CAV1—prostate cancer	2.59e-06	2.12e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CDKN1B—prostate cancer	2.59e-06	2.12e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CDKN1A—prostate cancer	2.59e-06	2.12e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SLC5A5—prostate cancer	2.59e-06	2.12e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PTEN—prostate cancer	2.59e-06	2.12e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CB—prostate cancer	2.59e-06	2.12e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—LDHB—prostate cancer	2.58e-06	2.11e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL2—prostate cancer	2.57e-06	2.1e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KDR—prostate cancer	2.57e-06	2.1e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTGS2—prostate cancer	2.56e-06	2.1e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—AKT1—prostate cancer	2.56e-06	2.09e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP3A5—prostate cancer	2.53e-06	2.07e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP2E1—prostate cancer	2.53e-06	2.07e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—APC—prostate cancer	2.53e-06	2.07e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CG—prostate cancer	2.53e-06	2.07e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ESR1—prostate cancer	2.5e-06	2.05e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NQO1—prostate cancer	2.5e-06	2.04e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGF—prostate cancer	2.5e-06	2.04e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IRS1—prostate cancer	2.5e-06	2.04e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CTNNB1—prostate cancer	2.48e-06	2.03e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EP300—prostate cancer	2.47e-06	2.02e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—TH—prostate cancer	2.46e-06	2.01e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CTNNB1—prostate cancer	2.45e-06	2e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PDHA1—prostate cancer	2.45e-06	2e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTA3—prostate cancer	2.45e-06	2e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TCN2—prostate cancer	2.45e-06	2e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—UCP3—prostate cancer	2.45e-06	2e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	2.45e-06	2e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—BAD—prostate cancer	2.44e-06	2e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP3A4—prostate cancer	2.44e-06	1.99e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CDKN1B—prostate cancer	2.43e-06	1.99e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDKN1A—prostate cancer	2.43e-06	1.98e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	2.42e-06	1.98e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—GSK3B—prostate cancer	2.42e-06	1.98e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PTEN—prostate cancer	2.42e-06	1.98e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—SRC—prostate cancer	2.4e-06	1.96e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP1B1—prostate cancer	2.4e-06	1.96e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—AKT1—prostate cancer	2.39e-06	1.96e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CDKN1A—prostate cancer	2.39e-06	1.96e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—INS—prostate cancer	2.39e-06	1.96e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTEN—prostate cancer	2.39e-06	1.95e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CG—prostate cancer	2.36e-06	1.93e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—APC—prostate cancer	2.36e-06	1.93e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CREBBP—prostate cancer	2.34e-06	1.92e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IRS1—prostate cancer	2.34e-06	1.91e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGF—prostate cancer	2.34e-06	1.91e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SLC22A3—prostate cancer	2.34e-06	1.91e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HSD3B1—prostate cancer	2.34e-06	1.91e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GGT1—prostate cancer	2.32e-06	1.9e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—STAT3—prostate cancer	2.31e-06	1.89e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IGF1—prostate cancer	2.31e-06	1.89e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EP300—prostate cancer	2.31e-06	1.89e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—EGFR—prostate cancer	2.3e-06	1.88e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CTNNB1—prostate cancer	2.29e-06	1.88e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NCOA1—prostate cancer	2.29e-06	1.87e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EP300—prostate cancer	2.28e-06	1.86e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—GSK3B—prostate cancer	2.27e-06	1.86e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP19A1—prostate cancer	2.25e-06	1.84e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—SRC—prostate cancer	2.24e-06	1.84e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CDKN1A—prostate cancer	2.24e-06	1.83e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TBXAS1—prostate cancer	2.24e-06	1.83e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTA4—prostate cancer	2.24e-06	1.83e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—INS—prostate cancer	2.24e-06	1.83e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAP2K1—prostate cancer	2.24e-06	1.83e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTEN—prostate cancer	2.23e-06	1.83e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CD—prostate cancer	2.22e-06	1.82e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—SRC—prostate cancer	2.21e-06	1.81e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SERPINE1—prostate cancer	2.2e-06	1.8e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CREBBP—prostate cancer	2.19e-06	1.79e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTA2—prostate cancer	2.18e-06	1.78e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—RXRA—prostate cancer	2.17e-06	1.78e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—KRAS—prostate cancer	2.17e-06	1.78e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—STAT3—prostate cancer	2.16e-06	1.77e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IGF1—prostate cancer	2.16e-06	1.77e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SULT1A1—prostate cancer	2.16e-06	1.76e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ABCG5—prostate cancer	2.16e-06	1.76e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—EGFR—prostate cancer	2.15e-06	1.76e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—STAT3—prostate cancer	2.14e-06	1.75e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EP300—prostate cancer	2.13e-06	1.74e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FGF2—prostate cancer	2.13e-06	1.74e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.11e-06	1.73e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTA1—prostate cancer	2.11e-06	1.72e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EGFR—prostate cancer	2.1e-06	1.72e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NOS3—prostate cancer	2.1e-06	1.72e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—COMT—prostate cancer	2.09e-06	1.71e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTP1—prostate cancer	2.08e-06	1.71e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NAT2—prostate cancer	2.08e-06	1.7e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTO1—prostate cancer	2.08e-06	1.7e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HSD3B2—prostate cancer	2.08e-06	1.7e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CD—prostate cancer	2.08e-06	1.7e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—SRC—prostate cancer	2.07e-06	1.7e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SERPINE1—prostate cancer	2.05e-06	1.68e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ITPR1—prostate cancer	2.05e-06	1.68e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—JAK2—prostate cancer	2.04e-06	1.67e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—KRAS—prostate cancer	2.03e-06	1.66e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.02e-06	1.65e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—STAT3—prostate cancer	2e-06	1.63e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CA—prostate cancer	2e-06	1.63e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—LRP2—prostate cancer	2e-06	1.63e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP2C18—prostate cancer	2e-06	1.63e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PLCB2—prostate cancer	2e-06	1.63e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MDM2—prostate cancer	1.99e-06	1.63e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FGF2—prostate cancer	1.99e-06	1.63e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KRAS—prostate cancer	1.99e-06	1.62e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MYC—prostate cancer	1.98e-06	1.62e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TGFB1—prostate cancer	1.98e-06	1.62e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EGFR—prostate cancer	1.97e-06	1.61e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NOS3—prostate cancer	1.96e-06	1.6e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ERBB2—prostate cancer	1.96e-06	1.6e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—P4HB—prostate cancer	1.96e-06	1.6e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EGFR—prostate cancer	1.94e-06	1.59e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—TYMS—prostate cancer	1.94e-06	1.59e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CB—prostate cancer	1.94e-06	1.58e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTM1—prostate cancer	1.92e-06	1.57e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—JAK2—prostate cancer	1.91e-06	1.56e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SLC22A1—prostate cancer	1.9e-06	1.56e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—LPL—prostate cancer	1.88e-06	1.54e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CA—prostate cancer	1.87e-06	1.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MDM2—prostate cancer	1.86e-06	1.52e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CXCL8—prostate cancer	1.86e-06	1.52e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KRAS—prostate cancer	1.86e-06	1.52e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MYC—prostate cancer	1.86e-06	1.52e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SULT2A1—prostate cancer	1.86e-06	1.52e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TGFB1—prostate cancer	1.85e-06	1.52e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ERBB2—prostate cancer	1.84e-06	1.5e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KRAS—prostate cancer	1.83e-06	1.5e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—MED12—prostate cancer	1.83e-06	1.49e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PIK3CA—prostate cancer	1.82e-06	1.49e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CDKN1B—prostate cancer	1.82e-06	1.49e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EGFR—prostate cancer	1.82e-06	1.49e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP1A1—prostate cancer	1.82e-06	1.49e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GNG5—prostate cancer	1.81e-06	1.48e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CB—prostate cancer	1.81e-06	1.48e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ERCC2—prostate cancer	1.8e-06	1.47e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CASP3—prostate cancer	1.78e-06	1.46e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL2—prostate cancer	1.78e-06	1.45e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL6—prostate cancer	1.77e-06	1.45e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NCOA3—prostate cancer	1.74e-06	1.43e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CXCL8—prostate cancer	1.74e-06	1.42e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCND1—prostate cancer	1.73e-06	1.42e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CTNNB1—prostate cancer	1.72e-06	1.4e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—KRAS—prostate cancer	1.72e-06	1.4e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CA—prostate cancer	1.71e-06	1.4e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CDKN1B—prostate cancer	1.7e-06	1.39e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—MTHFR—prostate cancer	1.69e-06	1.38e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CA—prostate cancer	1.68e-06	1.38e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MMP9—prostate cancer	1.68e-06	1.38e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CDKN1A—prostate cancer	1.68e-06	1.37e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PTEN—prostate cancer	1.67e-06	1.37e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CASP3—prostate cancer	1.67e-06	1.36e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HPGDS—prostate cancer	1.66e-06	1.36e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL2—prostate cancer	1.66e-06	1.36e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PPARA—prostate cancer	1.66e-06	1.36e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL6—prostate cancer	1.65e-06	1.35e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP2C19—prostate cancer	1.65e-06	1.35e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—AKT1—prostate cancer	1.63e-06	1.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCND1—prostate cancer	1.62e-06	1.33e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL6—prostate cancer	1.62e-06	1.32e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ACHE—prostate cancer	1.61e-06	1.32e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTT1—prostate cancer	1.61e-06	1.32e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CTNNB1—prostate cancer	1.61e-06	1.31e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP2A6—prostate cancer	1.6e-06	1.31e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EP300—prostate cancer	1.6e-06	1.3e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CA—prostate cancer	1.58e-06	1.29e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MMP9—prostate cancer	1.57e-06	1.29e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CDKN1A—prostate cancer	1.57e-06	1.28e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PTEN—prostate cancer	1.56e-06	1.28e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CAV1—prostate cancer	1.56e-06	1.28e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKR1C3—prostate cancer	1.55e-06	1.27e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SRC—prostate cancer	1.55e-06	1.27e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PRKACB—prostate cancer	1.54e-06	1.26e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP17A1—prostate cancer	1.53e-06	1.25e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—AKT1—prostate cancer	1.53e-06	1.25e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL6—prostate cancer	1.51e-06	1.24e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VEGFA—prostate cancer	1.51e-06	1.24e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—STAT3—prostate cancer	1.5e-06	1.22e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EP300—prostate cancer	1.49e-06	1.22e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—IL6—prostate cancer	1.49e-06	1.22e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.49e-06	1.22e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—AKT1—prostate cancer	1.49e-06	1.22e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NCOA2—prostate cancer	1.46e-06	1.19e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SRC—prostate cancer	1.45e-06	1.19e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CG—prostate cancer	1.42e-06	1.16e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VEGFA—prostate cancer	1.41e-06	1.16e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—STAT3—prostate cancer	1.4e-06	1.14e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—IL6—prostate cancer	1.4e-06	1.14e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—AKT1—prostate cancer	1.39e-06	1.14e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MYC—prostate cancer	1.39e-06	1.14e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.39e-06	1.14e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TGFB1—prostate cancer	1.39e-06	1.13e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—AKT1—prostate cancer	1.38e-06	1.13e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGFR—prostate cancer	1.36e-06	1.11e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.36e-06	1.11e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—INS—prostate cancer	1.35e-06	1.1e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NQO1—prostate cancer	1.34e-06	1.1e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TH—prostate cancer	1.32e-06	1.08e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CREBBP—prostate cancer	1.32e-06	1.08e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MYC—prostate cancer	1.3e-06	1.06e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TGFB1—prostate cancer	1.3e-06	1.06e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—AKT1—prostate cancer	1.29e-06	1.05e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.29e-06	1.05e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KRAS—prostate cancer	1.28e-06	1.05e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGFR—prostate cancer	1.27e-06	1.04e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CD—prostate cancer	1.25e-06	1.02e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GGT1—prostate cancer	1.25e-06	1.02e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NCOA1—prostate cancer	1.23e-06	1e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.21e-06	9.89e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KRAS—prostate cancer	1.2e-06	9.83e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NOS3—prostate cancer	1.18e-06	9.66e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CA—prostate cancer	1.18e-06	9.65e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—RXRA—prostate cancer	1.17e-06	9.55e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—prostate cancer	1.14e-06	9.34e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—COMT—prostate cancer	1.12e-06	9.2e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTP1—prostate cancer	1.12e-06	9.15e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CA—prostate cancer	1.1e-06	9.03e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ITPR1—prostate cancer	1.1e-06	9.01e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CB—prostate cancer	1.09e-06	8.91e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTGS2—prostate cancer	1.08e-06	8.83e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—prostate cancer	1.07e-06	8.74e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL6—prostate cancer	1.04e-06	8.55e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TYMS—prostate cancer	1.04e-06	8.51e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTM1—prostate cancer	1.03e-06	8.41e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—LPL—prostate cancer	1.01e-06	8.26e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL6—prostate cancer	9.78e-07	8e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP1A1—prostate cancer	9.75e-07	7.97e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ERCC2—prostate cancer	9.67e-07	7.91e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKT1—prostate cancer	9.64e-07	7.88e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTEN—prostate cancer	9.42e-07	7.7e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—MTHFR—prostate cancer	9.09e-07	7.43e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKT1—prostate cancer	9.02e-07	7.38e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—EP300—prostate cancer	8.98e-07	7.35e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PPARA—prostate cancer	8.91e-07	7.29e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CAV1—prostate cancer	8.38e-07	6.86e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CG—prostate cancer	7.63e-07	6.24e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—INS—prostate cancer	7.23e-07	5.91e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CREBBP—prostate cancer	7.08e-07	5.79e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CD—prostate cancer	6.71e-07	5.49e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CA—prostate cancer	6.64e-07	5.43e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NOS3—prostate cancer	6.34e-07	5.18e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CB—prostate cancer	5.85e-07	4.79e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTGS2—prostate cancer	5.8e-07	4.74e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AKT1—prostate cancer	5.43e-07	4.44e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTEN—prostate cancer	5.05e-07	4.13e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—EP300—prostate cancer	4.82e-07	3.94e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CA—prostate cancer	3.57e-07	2.92e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKT1—prostate cancer	2.91e-07	2.38e-06	CbGpPWpGaD
